Health-food OEM,designed for market.

Yes. JSH can turn an early concept into a commercially viable product specification by reviewing market trends, selecting primary and supporting ingredients, setting use levels, and planning the dosage form and packaging.

Yes, where appropriate. JSH can source patented and branded ingredients from Japan, Europe, the United States, and other markets, while confirming authorization, technical documentation, and supply conditions with the manufacturer.

Ownership can be arranged according to the commercial structure of the project. Formula rights, confidentiality obligations, and any market exclusivity will be defined clearly in the project agreement.

Yes. JSH can coordinate technical communication, production conditions, quality review, cross-border logistics, and import documents, giving international clients one point of contact for a Japanese OEM project.

JSH reduces the language and coordination burden of a cross-border project. We use our Japanese supply network to compare production conditions, schedules, and documentation requirements, and help align decisions at each stage.

Timing depends on the formula, dosage form, trial production, and packaging. From formula approval to delivery of the first commercial batch in Taiwan, a typical planning range is four to six months. A project-specific schedule will be provided after review.

A preliminary planning range is six to eight months, covering scientific substantiation, dossier preparation, and the authority's filing process. Actual timing depends on the ingredient, evidence, and completeness of the documentation.

Yes. Depending on the project, JSH can coordinate materials for clinical studies, review the available evidence, and prepare systematic-review documentation aligned with Japanese requirements.

It may increase the complexity of interaction assessment, stability testing, and scientific substantiation. We generally recommend defining a core functional component or establishing an evidence plan that supports the complete formula.

Minimums vary by dosage form and factory. A common range is tens of thousands to around one hundred thousand tablets or capsules, or an equivalent production batch. JSH compares suitable options based on the product specification.

Yes. Accelerated stability testing, storage-condition checks, and packaging-compatibility evaluations can be arranged according to the product's risk profile.

Usually, yes. Setup costs and production losses are distributed across fewer units. However, a pilot batch can reduce inventory exposure and market-validation risk before a full launch.

The ingredient's regulatory status, permitted food use, and supporting scientific evidence must be confirmed first. JSH can screen options such as dietary fiber and protein peptides for the target market, without positioning the product as having a medical effect.

Drinks, powders, capsules, or oral films may be considered based on the ingredients, daily use level, and consumption setting. The final format must also satisfy stability, regulatory, and consumer-experience requirements.

Advertising should undergo professional regulatory review. Claims must avoid disease treatment, pharmaceutical action, or unsupported physiological effects, and every statement should remain consistent with the product's evidence.

This requires a case-by-case review of the ingredient's regulatory status, manufacturing process, specification, and the authority's interpretation. JSH can provide Japanese manufacturing and quality documentation, but cannot guarantee that any ingredient or product will be permitted in a particular market.

It can combine strain selection, fermentation, extraction, and standardization technologies, supported by data on purity, stability, and batch-to-batch quality for commercial product design.

Drinks, powdered beverages, capsules, and other formats can be evaluated according to solubility, flavor, and stability, then selected to fit the target consumer and market proposition.